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Abstract
Background: Osteoporosis is the gradual declining in bone mass with age, leading to increased bone fragility and fractures.
Fractures in hip and spine are known to be the most important complication of the disease which leads in the annual mortality
rate of 20% and serious morbidity rate of 50%. Menopause is one of the most common risk factors of osteoporosis. After
menopause, sex hormone deficiency is associated with increased remodeling rate and negative bone balance, leading to
accelerated bone loss and micro-architectural defects, resulting into increased bone fragility.
Compounds with estrogen-like biological activity similar to "Isoflavones" present in plants especially soy, may reduce bone loss
in postmenopausal women as they are similar in structure to estrogens.
This research, therefore, was carried out to study the effects of Iranian soy protein on biochemical indicators of bone
metabolism in osteopenic menopausal women.
Materials and methods: This clinical trial of before-after type was carried out on 15 women 45–64 years of age. Subjects
were given 35 g soy protein per day for 12 weeks. Blood and urine sampling, anthropometric measurement and 48-h-dietary
recalls were carried out at zero, 6 and 12 weeks. Food consumption data were analyzed using Food Proccessor Software. For
the study of bone metabolism indicators and changes in anthropometric data as well as dietary intake, and repeated analyses
were employed.
Results: Comparison of weight, BMI, physical activity, energy intake and other intervening nutrients did not reveal any significant
changes during different stages of the study. Soy protein consumption resulted in a significant reduction in the urinary
deoxypyridinoline and increasing of total alkaline phosphatase (p < 0.05), although the alterations in osteocalcin, c-telopeptide,
IGFBP3 and type I collagen telopeptide were not significant.
Conclusion: In view of beneficial effect of soy protein on bone metabolism indicators, inclusion of this relatively inexpensive
food in the daily diet of menopausal women, will probably delay bone resorption, thereby preventing osteoporosis.
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Backgrounds
Menopause is a period normally occupying one-third of
women's life [1]. Reduced bone density is one of the most
prominent symptoms during menopause [2].
Osteoporosis is a serious problem for postmenopausal
women which increases the risk of bone fracture and
worsens with age, increasing from 4% in 50–59 year age
bracket to 50% in 80 years old women. Bone fractures are
also prevalent in these women [3]. Today estrogen therapy
(ERT) and drugs like bisphosphonates, calcitonin and
raloxifene is employed to prevent and treat osteoporosis
[4]. However, side effects such as breast cancer, endome-
trial adenocarcinoma [5] have limited the acceptance of
these medications among women [6] and only 35% to
40% of women ever start ERT, and many do not continue
it [7].
Epidemiologic studies have shown osteoporotic fractures,
cardiovascular disease, postmenopausal symptoms and
some cancers to be less prevalent in Asians compared to
their western counterparts. Hip fracture, for example, is
50–60% less frequent among Asian compared to western
women [8]. This advantage is gradually anihilated as
Asian adapt western lifestyle [9]. These observations,
prompted researchers to scrutinize Asian dietary habits.
Soy is a part of Asian traditional diet [10], showing some
relationship with the above-mentioned diseases [9].
Estrogen-like compounds such as isoflavones existing in
plant foods specially soy [11,12] can curb reduced bone
density in menopausal women, due to their structural
similarity [13]. Some studies have not, however, sup-
ported clearly the role of soy isoflavones in preventing
osteoporosis [14].
Isoflavones are phyto-estrogens similar to women's estro-
gens and are bound to cellular estrogen receptors in vari-
ous organs, thus phytoestrogens affinity is weak
compared to human's estrogens. Recent studies have
shown that cells have two types estrogen receptors α and
β. Human estrogens have more affinity to α-receptors,
whereas, isoflavones have high affinity to β-receptors. β-
receptors exist in brain, bone, bladder and vascular epi-
thelium, being important in the function of non-steroid
estrogens [15].
As soy cultivated in Iran is of different variety, namely
"Gorgan" compared to other studies and because the Ira-
nian food habits and food pattern is different [16] which
might affect the metabolism of nutrients and isoflavones,
this study was conducted to assess its effects compared to
other countries. Furthermore there are still contradiction,
in the literature regarding the role of soy isoflavones
which justify implementation of this study.
Methods
This clinical trial of before and after type was carried out
in 2003. Women referring to the osteoporosis clinic of
Endocrinology & Metabolism Research Centre of Tehran
University of Medical Sciences for bone density measure-
ment were screened to find osteopenic subjects and 15
postmenopausal 45–64 year old women were selected.
Those women between 1 to 10 years postmenopause who
were non-smokers and free from diseases entered this
study.
Information on weight, height, body mass index, two 24-
hr food consumption recall and physical activity were col-
lected at the start, 6 and 12 weeks of the study. Soy protein
at 35 g level containing 98.3 mg isoflavones were given to
subjects daily. Subjects were provided with a special cup
for measuring soy. Cooking instructions were also given
to the subjects.
Blood and urine samplings were done in 3 stages, in the
beginning and at the end of 6th and 12th week. Blood and
urine samples were kept frozen until the end of the twelfth
week at -80°C. Serum biochemical indicators were meas-
ured on the same day for all samples. Total alkaline phos-
phatase was assayed calorimetrically with Hitachi 902
autoanalyzer, osteocalcin by IRMA method using Bio-
source kit and Wizard gamacounter, IGFBP3 and c-tel-
opeptide by ELISA using Biosources and Bioscience
diagnostics respectively. Type I collagen telopeptide was
determined by RIA method using Orion-Diagnostica on
Wizard gama counter and urinary creatinine by colorimet-
rically method [17]. Food Processor software was used for
food consumption survey and SPSS (version 11.5) was
employed for statistical analysis of the data. All quantita-
tive variables were then examined by Kolmogrof-Smirnof
(KS) to ensure normality of distribution. To analyze any
possible changes in food intake, intervening and bio-
chemical variables in 3 stages, repeated measurement
analysis was utilized. The purpose of this analysis was to
ensure lack of significant changes of the variables. Signifi-
cance level was set at below 5 percent (P < 0.05).
Results
Subjects' anthropometric data are shown in Table 1. Mean
age was 52.9 ± 4.3 years, years post menopause 5.47 ± 3.4
years and mean height 157.4 ± 7.2 centimeters. Mean
body mass index and physical activity level remained
unchanged. Mean food consumption figures were not dif-
ferent at 6 and 12 weeks compared to the start of the study
(Table 2). Mean bone metabolic indicators for the 3 stages
are given in Table 3. After 12 weeks of soy consumption
total serum alkaline phosphatase (TALP) significantly
increased while urinary deoxypyridinoline (DPD)
decreased (P < 0.05). Other indicators namely osteocal-
cin, insulin growth factor binding protein (IGFBP3), c-tel-Nutrition Journal 2005, 4:30 http://www.nutritionj.com/content/4/1/30
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opeptide and type-I collagen telopeptides did not change
significantly.
Discussion
The results demonstrated soy protein consumption to
have caused increase in TALP and reduction in DPD in
menopausal women with osteopenia, while other param-
eters were not significantly difference. Comprehensive
human studies on the effect of soy on TALP have not been
carried out. In Arjmandi et al studies on rats a slight but
insignificant increase in TALP was seen [18-20]. The cru-
cial role of gut microflora in the metabolism of isofla-
vones in human beings has also been previously explored
[21]. In vivo studies proved that bacteria in the gastroin-
testinal tract play an important role in determining the
magnitude and pattern of isoflavone bioavailability [22].
However, only 30 to 40% of the population can produce
equol from daidzein and interindividual differences in the
bacteria responsible for equol production [23,24]. Regis-
ter et al observed a significant fall in TALP in monkeys
after 12 weeks [25]. Animal models such as monkey may
convert daidzein into equol more readily than 30 to 50%
of humans. It has been shown that equol possesses more
estrogen-like properties than daidzein. This is why isofla-
vone efficacy has been less pronounced in monkeys and
the results have been reported as reduced TALP levels
[26,27].
TALP is an insensitive marker for bone formation com-
pared to bone-specific alkaline phosphatase (BAP) or
osteocalcin (OC). In this study, serum osteocalcin as a
sensitive marker for bone formation has not changed dur-
ing interventional period, indicating that soy protein may
not enhance bone formation.
With regard to bone resorption, our results showed
reduced urinary DPD levels following soy consumption
which agrees with the finding of other investigators [28-
30]. The effect of isoflavones on this indicator is so strong
that Uesagi et al [31] observed consuming 61.8 mg of iso-
flavone for 4 weeks results in a significant reduction in uri-
nary DPD. It can be said that DPD acts as a bridge between
collagen fibrils which enter urine with collagen break-
down. As this is a very specific marker for bone resorption,
its significant reduction in our study suggests soy con-
sumption may prevent degradation of collagen the major
protein in bone matrix [17].
Other serum indicators of bone metabolism were not
affected in our study. In most studies on the effects of iso-
flavones in rats these phytochemicals, have been reported
to have caused rises [32], no change [19,20] and even
reduction [14] in bone formation as well as reduction or
no change [33,34] on bone resorption. The changes
observed in this study, therefore, are not contradictory to
other studies and slight differences observed may be
attributed to sample size, isoflavone dosing, period of
intervention and dissimilarity of the studied groups.
Conclusion
In conclusion it seems soy protein can be effective in pro-
tecting bone mass through curbing bone resorption spe-
cially in high risk groups as was demonstrated in our
osteopenic subjects but not enhance bone formation. Dif-
ferent studies have reported intake of 70–90 milligrams of
isoflavones per day to be effective. Soy protein in our
study provided 98 mg of isoflavones which is in accord-
ance with other studies [35,36]. Some have reported lesser
amounts can be effective in longer periods of time [37].
Soy protein consumption, thus, is a valuable plant estro-
Table 1: Subjects anthropometric data in 3 stages of the study (n = 15).
Indicators At the start 6 weeks 12 weeks
Weight (kg) 68 ± 7.5* 68 ± 7.6 68 ± 7.8
BMI (kg/m2) 27.4 ± 3** 27.4 ± 3 27.4 ± 3
* Mean ± SD
** Mean height was 157.2 ± 7.2.
Table 2: Subjects mean food intake in 3 stages of the study (n = 15).
Variables at the start 6 weeks 12 weeks P value**
Energy (kcal) 1933.4 ± 302.5* 2033.2 ± 420.3 1902.8 ± 308.6 NS***
Protein (g) 74.6 ± 12.3 71.9 ± 17.4 74.8 ± 10.2 NS
Calcium (mg) 999.3 ± 460.2 966.8 ± 443.7 1014 ± 436 NS
Phosphore (mg) 873.2 ± 228.9 853.1 ± 273.9 866.4 ± 200.6 NS
* Mean ± SD
** significant level was set at below 5 percent (P < 0.05).
*** To analyze changes in 3 stages, repeated measurement analysis was utilized.Nutrition Journal 2005, 4:30 http://www.nutritionj.com/content/4/1/30
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gen which can be recommended for osteoporosis preven-
tion.
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